Rajendra, V. K. P., Kurapati, S., Balineni, S. K., &
INNOVATIVE TECHNOLOGIES
Gogineni, N. T. T. (2022). Functional Foods in Health and Disease, 12(7), 361-179.
- Study Design: Randomized, double-blind, placebo-controlled trial
- Subjects: 88 adult men and women
- Intervention: Subjects were administered one of the following:
1. 300mg once daily (300mg/day) of 4’Liver™
2. 320mg once daily (320mg/day) of Milk Thistle Seed Extract
3. Matching placebo
- Study Duration: 12 weeks
Liver Study
Percent change in liver health measurements including fatty liver index (FLI), gamma-glutamyl transferase (GGT), alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and albumin/globulin ratio
(A/G ratio) from baseline to week 12.* Indicates a statistically significant (p < 0.05) change over time for a given liver health measurement as compared to the placebo group.
Percent change in lipid profile measurements including fatty liver index (FLI), low-density lipoprotein (LDL) cholesterol, and total cholesterol (TC) from baseline to week 12. * Indicates a statistically significant (p < 0.05) change over time for a given lipid profile measurement as compared to the placebo group.
Percent change in various measurements of antioxidant status, including reduced glutathione (GSH) and superoxide dismutase (SOD) as well as measurements of oxidative stress including malondialdehyde (MDA), and thiobarbituric acid reactive substances (TBARS) from baseline to week 12. * Indicates a statistically significant (p < 0.05) change over time for a given measurement as compared to the placebo group.
“Percent change in 2 domains of the Short Form-36 health survey (SF-36), including physical functioning and vitality, from baseline to week 12. * Indicates a statistically significant (p < 0.05) change over time for a given domain as compared to the placebo group. “
Percent change in the total gastrointestinal symptom (GIS) score as well as on two domains including epigastric discomfort and general intestinal symptoms, from baseline to week 12. * Indicates a statistically significant (p < 0.05)
change over time for the total or a given domain as compared to the placebo group.
